Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)

v3.21.1
Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Antidilutive securities excluded from computation of diluted weighted shares outstanding 26,117,340 24,254,443
PAVmed Inc. 2014 Equity Plan Stock Options and Restricted Stock Awards [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 8,539,362 5,795,195
Unit Purchase Options as to Shares of Common Stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53,000
Unit Purchase Options as to Shares Underlying Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53,000
Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 15,954,722 16,815,039
Series W Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 381,818 381,818
Series B Convertible Preferred Stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding [1] 1,241,438 1,156,391
[1] If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in a correspondingthe issue of the same number of additional outstanding shares of common stock of the Company.